PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
Rafael Rosell;,Ramn Palmero;

..............page:71-73

Tumor immune microenvironment characterization and response to anti-PD-1 therapy
Mariacarmela Santarpia;,Niki Karachaliou;

..............page:74-78

Understanding the function and dysfunction of the immune system in lung cancer:the role of immune checkpoints
Niki Karachaliou;,Maria Gonzalez Cao;,Cristina Teixid;,Santiago Viteri;,Daniela Morales-Espinosa;,Mariacarmela Santarpia;,Rafael Rosell;

..............page:79-86

Assays for predicting and monitoring responses to lung cancer immunotherapy
Cristina Teixid;,Niki Karachaliou;,Maria Gonzlez-Cao;,Daniela Morales-Espinosa;,Rafael Rosell;

..............page:87-95

Changes in tumor-antigen expression proifle as human small-cell lung cancers progress
Li-Sheng Ge;,Neil T Hoa;,Nils Lambrecht;,Maria Dacosta-Iyer;,Yi Ouyang;,Amir Abolhoda;,Martin R Jadus;

..............page:96-105

Current approaches in treatment of triple-negative breast cancer
Hanan Ahmed Wahba;,Hend Ahmed El-Hadaad;

..............page:106-116

Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs:a systemic review and meta-analysis
Jie-Ying Chen;,Ya-Nan Cheng;,Lei Han;,Feng Wei;,Wen-Wen Yu;,Xin-Wei Zhang;,Shui Cao;,Jin-Pu Yu;

..............page:126-140